Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Abstract Background This prospective study aims to investigate the efficacy and safety of pyrotinib (P) combined with 4 cycles of epirubicin and cyclophosphamide followed by 4 cycles of taxane and trastuzumab (P + EC-TH) regimen as neoadjuvant therapy for human epidermal growth factor receptor 2 (HE...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2023-12-01
|
| Colección: | World Journal of Surgical Oncology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12957-023-03266-5 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|